Roflumilast Cream 0.3%

DRUG3 trials

Sponsors

Arcutis Biotherapeutics, Inc., Padagis LLC, Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

Conditions

Plaque Psoriasis

Phase 2

The Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream in Subjects With Chronic Plaque Psoriasis

CompletedNCT03638258

Arcutis Biotherapeutics, Inc.Plaque Psoriasis

Start: 2018-09-21End: 2019-05-29Updated: 2022-09-02

Phase 3

Bioequivalence Study of Two Treatments for the Treatment of Plaque Psoriasis

CompletedNCT05763082

Padagis LLCPlaque Psoriasis

Start: 2023-02-07End: 2023-08-08Updated: 2026-08-26

Efficacy and Safety of Roflumilast Cream 0.3% in Subjects With Plaque Psoriasis: a Phase 3 Study

CompletedNCT06648772

Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.Plaque Psoriasis

Start: 2024-11-14End: 2025-10-15Updated: 2026-07-06

Related Papers

Effect of Roflumilast Cream (ARQ-151) on Itch and Itch-Related Sleep Loss in Adults with Chronic Plaque Psoriasis: Patient-Reported Itch Outcomes of a Phase 2b Trial

American Journal of Clinical Dermatology2022-11-1210 citations

Trial of Roflumilast Cream for Chronic Plaque Psoriasis

New England Journal of Medicine2020-07-15113 citations